Zelgen(SH:688266) Xin Lang Cai Jing·2025-11-17 06:00Group 1 - Zejing Pharmaceutical (688266.SH) plans to issue overseas listed shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international brand recognition and competitiveness [1][2] - The company is currently in discussions with relevant intermediaries regarding the issuance and listing, with specific details yet to be finalized [1] - As of November 17, 2025, Zejing Pharmaceutical's total market capitalization is approximately 27.133 billion RMB [2] Group 2 - Established in 2009, Zejing Pharmaceutical has five subsidiaries and focuses on the independent research, production, and commercialization of innovative drugs [2] - The company aims to become a leader in the development and production of new drugs for oncology, bleeding and blood diseases, and immune-inflammatory diseases [2] - Zejing Pharmaceutical has developed two core technology platforms for small molecule drug research and complex recombinant protein new drugs, covering various cancers and treatment areas [2]